Quadruple therapy shows 100 percent SVR for HCV patients previously unresponsive to treatment

New data show that quadruple therapy in chronic hepatitis C (HCV) patients suppressed the emergence of resistant variants and resulted in a 100 percent rate of sustained virological response — undetectable HCV RNA — 12 weeks after treatment (SVR12).